In This Section

Continuing Medical Education

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


Credit Designation Statement

AACR has designated this internet live activity for a maximum of 9.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, November 11, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Statement of Educational Need, Target Audience, and Learning Objectives

According to the U.S. National Cancer Institute, pancreatic cancer will account for approximately 48,220 deaths in 2021. Pancreatic cancer will account for just 3.2% of all new cancer cases but will account for 7.9% of all cancer deaths.  Despite advances in recent years, the 5-year survival rate is only at 10.8% – making pancreatic cancer one of the most lethal malignant neoplasms.1

Because patients seldom exhibit symptoms until an advanced stage of the disease, early detection and diagnosis are a primary area of concern in pancreatic cancer research. 2 With talks dedicated to highlighting recent clinical advances made in epidemiology, “omic” big data, the tumor microenvironment, and translating immunotherapy for pancreatic cancer patients, the conference has the potential to educate physicians about wider and upcoming treatment options for improved patient outcomes.

After participating in this CME activity, physicians should be able to:

  1. Identify molecular drivers as novel potential therapeutic targets in pancreatic cancer.
  2. Assess immunological, metabolic, and tumor microenvironmental contributions towards pancreatic cancer initiation, progression and treatment response.
  3. Articulate the role of tumor microenvironment in influencing pancreatic cancer disease states.
  4. Evaluate recent clinical advances made in treating pancreatic cancer.
  5. Assess therapeutic strategies that combine genomic research with precision medicine.
  6. Explain the role of epidemiological trends and health inequities in pancreatic cancer.

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available on the website of this conference.

Acknowledgment of Financial or Other Support

This activity is supported by Professional Educational Grants which will be disclosed at the meeting.

Questions about CME?

Please contact the Office of CME at (215) 440-9300 or [email protected].